Introduction nonreciprocal translocation containing a distal portion of chromosome 15 fused to the majority of chromosome A hallmark of tumorigenesis is genomic instability, which 12, der(12)t(12;15), which we hereafter refer to as C12;15 manifests as chromosomal aberrations such as translo-(with C identifying the derivative chromosome containing cations and amplifications (reviewed in Lengauer et al., the centromere). Moreover, the X/P and L/P lymphomas, 1998). While these changes can be simple, such as balas well as the Ku80 Ϫ/Ϫ ,p53 Ϫ/Ϫ lymphomas, contain subanced reciprocal translocations or localized gene amplistantial amplification of both c-myc and segments of fication, many involve complex unbalanced translocathe IgH locus. The chromosomal alterations in these tions associated with amplification of sizable regions.
tumors were noted to be reminiscent of those in human The latter events, which we refer to collectively as comBurkitt's lymphomas (Difilippantonio et al., 2000) . Howplicons, have been noted in association with pathogeneever, the relationship between the recurrent chromosis and progression of various solid and disseminated some 12 and 15 translocations and c-myc/IgH amplificacancers (Coene et common mechanism for anticancer drug resistance, and of drug resistance (Livingstone et al., 1992; Yin et al., 1992) . In this regard, p53 deficiency was suggested to also as a characteristic of an ever-increasing number of human tumors (reviewed in Kuehl and Bergsagel, allow cells to move inappropriately into S phase and acquire DSBs that initiate amplification (Paulson et al., 2002; Schwab, 1999) . In the latter context, amplification commonly results in overexpression of cellular onco-1998). On the other hand, it also is conceivable that checkpoint deficiencies allow replication of preexisting genes and has been implicated in several stages of tumor development (Lengauer et al., 1998). Studies of DSBs, thus creating chromatid substrates for BFB amplification. acquired drug resistance in transformed cell lines have led to the articulation of several different models for In contrast to standard amplification in drug-resistant cells, little is known about the mechanism of complicon gene amplification. Broadly, these models include unequal sister chromatid exchange, extrachromosomal formation in the context of cytogenetic tumor progression. Herein, we report that X/P and L/P mice reproducibly amplification and reintegration, localized overreplication, and breakage-fusion-bridge cycles (reviewed in succumb to pro-B cell lymphomas that feature complicons harboring coamplified c-myc and IgH sequences. Stark, 1993) .
Cytogenetic evidence suggested that DNA breakage In addition, we elucidate, in detail, the molecular mechanism by which these complicons arise. could play a key role in amplification (Windle et al., 1991 2000) , than levels in a normal adult thymus ( Figure 1C) , the confirming pro-B lymphocyte origin. normal tissue that exhibits highest c-myc expression To assay for c-myc amplification, tumor DNA was (Zimmerman and Alt, 1990 ). analyzed by Southern blotting for hybridization with a promoter-proximal c-myc probe. All but two of 20 anaRequirement for RAG in Pro-B Lymphomagenesis lyzed X/P or L/P pro-B lymphomas showed substantial in X/P Mice amplification ( Figure 1A; Figures 2B and 2D) , and in tumor #127 the coamplified IgH/c-myc was on from nine separate translocation junctions were analyzed and mapped to the single nucleotide level. In all the chromosome 6 derivative (data not shown).
None of the tumors analyzed routinely contained even cases, translocation junctions contained very short (1-6 nucleotides) sequence homologies ( Figure 3A) , sugsingle-copy IgH or c-myc sequences on the C12;15 (e.g., Figures 2B and 2D) , although a subset of tumor #127 gesting involvement of an end-joining pathway, still not well characterized, that employs such short homologies metaphases contained apparently low or single-copy IgH and c-myc on a C12;15 and a C15;12 (data not (Roth and Wilson, 1986 ). There was no apparent nucleotide addition at any of these junctions. Germline sequences shown). As neither the C15;12-nor the C12;15-containing c-myc were observed in any other tumors, we surrounding chromosome 12 and 15 breakpoints contained no significant sequence homologies. Likewise, speculate these translocations may represent complicon-related by-products and/or independent translocano obvious RSSs were found in the sequences closely flanking the chromosome 15 breakpoints. tion events in tumor #127. To further characterize the (Table 1) , its junction 5Ј of c-myc did not clusters were observed, including three junctions within Figure 3B . 
